Toragen

About Toragen

Toragen is a clinical-stage biotechnology company focused on developing cancer treatments targeting viral-associated cancers, with an emphasis on HPV-induced cancers such as head and neck squamous cell carcinoma. The company describes its lead program and small molecule, TGN-S11, which inhibits the E5 oncogene protein and has entered a Phase I clinical trial in HPV-associated malignancies. Located in San Diego, California,Toragen aims to progress from early clinical studies toward combination strategies, including potential anti-PD-1 immunotherapy approaches. The organization highlights its team’s experience in translational drug development and pivotal clinical trials relevant to viral-driven oncology.